Ongoing Pathogenic Virus Challenges

Virion-Ctrl™ is a solution for both detection and protection to slow the transmission of pathogenic virus particles.  It involves the early warning detection of asymptomatic and pre-symptomatic carriers of SARS-CoV-2 and coronavirus active virions. Globally deployed RT-PCR testing is ineffective as it measures RNA, not the S1 spike protein, several days late in the infection cycle, presenting false negatives, false positives and re-positives. Thermal testing is also ineffective as asymptomatics and pre-symptomatics are afebrile. Therefore, relying solely on these testing methods amplifies the risk of continued outbreaks.

PPE N95 respiratory masks, widely used by healthcare workers, have a filtration efficiency of 95% at removing particles of 0.30 μm diameter. This provides only partial protection against the SARS-CoV-2 virion having a diameter of 0.05 to 0.20 μm. HVAC systems are also only partially effective in filtering out submicron virions where non-active filtering with the necessary porosity would substantially disrupt airflow.

There is a substantial research objective on all inhabited continents to develop an effective vaccine for SARS-CoV-2 that provides a longer lasting immune response and able to protect against emerging variants.

It is essential that present Point-of-Care testing methods  using 15 minute Lateral Flow Test strips be upgraded to digital in order to provide rapid  viral load data to the CDC, WHO and reporting agencies managing clustermaps.

Our Virion-Ctrl Entry Management System is an advanced antigen/epitope testing method using saliva samples on inexpensive electrochemical test strips. Wireless communication is performed in less than 60 seconds with pertinent data including quantitative viral load.